ArticleThe journal of headache and pain2026
Genetic subtraction reveals divergent pathways and targets in anxiety-related and anxiety-independent TMD.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTemporomandibular disorders (TMD) show substantial clinical and genetic overlap with anxiety, yet it remains unclear whether TMD risk reflects shared anxiety-related liability or distinct anxiety-independent genetic mechanisms. Disentangling these components is essential for understanding TMD heterogeneity beyond symptom-based classifications.
methodsWe applied GWAS-by-subtraction using genome-wide summary statistics for TMD (20,799 cases and 479,549 controls; FinnGen Release 12) and anxiety disorders (74,973 cases and 400,243 controls), partitioning TMD heritability into two orthogonal latent components: an anxiety-dependent factor (FAnxiety) and an anxiety-independent factor (FNon-Anxiety). To delineate the mechanisms underlying each component, we integrated fine-mapping, transcriptome- and proteome-wide association analyses, genetic colocalization, brain imaging–genetics, and single-cell RNA sequencing from human embryonic temporomandibular joint tissue.
resultsAnxiety showed significant genetic correlation with TMD (rg = 0.4417, p = 1.98 × 10− 1 9) and accounted for 19.50% of TMD heritable variance. FAnxiety yielded multiple genome-wide significant loci (CNTNAP5, PCLO, PRSS16, BTN1A1, RAB27B), whereas FNon-Anxiety produced a single independent signal near GPNMB, demonstrating sharply divergent genetic architectures. Multi-omic integration identified RAB27B as a driver of the anxiety-related pathway, implicating synaptic vesicle trafficking and neuroimmune regulation, while GPNMB and KLHL7 supported anxiety-independent pathways involving musculoskeletal remodeling and peripheral inflammation. BrainXcan analyses showed that FAnxiety predominantly affected limbic and external capsule microstructure, whereas FNon-Anxiety mapped to thalamic–sensorimotor white matter networks. Single-cell mapping further revealed distinct enrichment patterns of RAB27B, KLHL7, and GPNMB across TMJ cell types.
conclusionThese findings demonstrate that TMD genetic liability comprises separable anxiety-related and anxiety-independent dimensions with distinct molecular, neurostructural, and cellular signatures. Rather than defining clinical subtypes, these latent components represent associative dimensions of genetic risk at the population level. This integrative framework clarifies the genetic architecture underlying TMD heterogeneity and provides a foundation for future studies integrating individual-level phenotyping to assess clinical relevance and causal mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.